Last checked at 26 Sep 2023 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Belluscura plc
("Belluscura" or the "Company")
Belluscura Receives Approval and First Purchase Order in Hong Kong and commences the manufacture of the first DISCOV-RTM units
Belluscura secures its first approval in phase one of its exclusive license agreement with Innomax Licensing Agreement
LONDON, U.K. and PLANO, TX, U.S. (26 September 2023). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received approval from the Hong Kong Department of Health - Medical Device Division to distribute the X-PLOR® portable oxygen concentrator.
Belluscura has already received its first purchase order from a Hong Kong distributor. Hong Kong is part of the licensed territory in its Exclusive License Agreement signed last month with Innomax Medical Device Technologies.
The Company is also pleased to announce the successful completion of the DISCOV-R™ portable oxygen concentrator patient usability study with all participants providing favorable feedback on the device. Initial production of the DISCOV-R™ will commence this week. Full-scale production is being planned in conjunction with Innomax in response to the significant preliminary demand already received by the Company.
Bob Rauker, Chief Executive Officer, Belluscura plc, commented:
"We are very excited to receive the approval and begin sales in Hong Kong. I am very pleased with our operations, quality control and sales teams receiving approval ahead of schedule. Hong Kong is phase one of our joint expansion with Innomax into Asia."
For further information please contact:
Belluscura plc | Tel: +44 (0)20 3128 8100 |
Adam Reynolds, ChairmanRobert Rauker, Chief Executive OfficerAnthony Dyer, Chief Financial Officer | |
SPARK Advisory Partners Limited Nominated Adviser | Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat | |
Dowgate Capital Limited Broker | Tel: +44 (0)20 3903 7715 |
Russell Cook/Nick Chambers | |
MHP Financial PR & Investor Relations | Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
Katie Hunt/Matthew Taylor |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.